Lung Cancer Clinical Trial

Feasibility of Exercise With Post-Op Lung Cancer Patients

Summary

Primary Objective: To examine the effects of an exercise training program on cardiopulmonary fitness in early-stage postoperative non-small cell lung cancer patients undergoing adjuvant chemotherapy

Secondary Objectives:

Determine patients' adherence levels to such a program during adjuvant chemotherapy Explore the effects of exercise training on treatment compliance and toxicity, and quality of life.

To explore the effects of exercise training on markers of inflammation (e.g., c-reactive protein, immune response) in patients undergoing adjuvant chemotherapy for early-stage non-small cell lung cancer

View Full Description

Full Description

Using a single-group, prospective design, potential participants will be identified and screened for eligibility by the PI (LWJ) via medical record review of patients scheduled for their primary adjuvant chemotherapy consultation at DUMC and Durham VA. As a routine part of clinical care, during the treatment consultation the attending oncologist will perform a physical examination to screen for cardiovascular risk factors, the results of which will be recorded in the patients' medical records. Immediately following their consultation and oncologist approval, potential participants will be provided with a thorough review of the study by the principal investigator (LJ) and asked if they are willing to participate. Interested participants will be given an information package that provides further information on study participation. Two to five days following their treatment consultation and prior to the initiation of chemotherapy, interested participants will be contacted by telephone by the PI to answer any questions and to schedule the baseline assessment visit. At the baseline visit, participants will be asked to sign the informed consent and will be given a copy for their records. After consent, they will be given a baseline ECG and physician monitored cardiopulmonary exercise test (stress test) to screen for undiagnosed cardiovascular disease. Following the successful completion of baseline assessments, all participants will be scheduled for their initial exercise training session. Finally, on a different group of patients we will perform a random retrospective medical chart review of 50 completely-resected NSCLC patients who received usual care (i.e., no exercise training) during the study period to obtain comparative information on the treatment toxicity/compliance rate. The chart review will be performed by Drs. Jones, Garst and Crawford and will assess treatment toxicity and compliance over the entire course of adjuvant chemotherapy.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Legal age (>18 years old)
Absence of contraindications to chemotherapy
Ability to read and understand English
Signed informed consent prior to the initiation of study procedures
Primary attending oncologist approval.

Exclusion Criteria:

Acute myocardial infarction (3-5 days)
Unstable angina
Uncontrolled arrhythmias causing symptoms or hemodynamic compromise
Syncope
Acute endocarditis
Acute myocarditis or pericarditis
Uncontrolled heart failure
Acute pulmonary embolus or pulmonary infarction
Thrombosis of lower extremities
Suspected dissecting aneurysm
Uncontrolled asthma
Pulmonary edema
Room air desaturation at rest ≤85%
Respiratory failure
Acute noncardiopulmonary disorder that may affect exercise performance or be aggravated by exercise
Mental impairment leading to inability to cooperate.
Finally, patients presenting with no medical history will not be eligible for study participation.

Study is for people with:

Lung Cancer

Estimated Enrollment:

21

Study ID:

NCT00636571

Recruitment Status:

Completed

Sponsor:

Duke University

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Duke University Health System Preston Robert Tisch Brain Tumor Center
Durham North Carolina, 27710, United States

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Estimated Enrollment:

21

Study ID:

NCT00636571

Recruitment Status:

Completed

Sponsor:


Duke University

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider